2024-09-30 16:14:37
September 30, 2024 | 18.14
READ: 2 minutes
“Blinatumomab bispecific antibody is the first drug approved to treat minimal residual disease (MRD) in a leukemia. In recent years, for those involved in oncohaematology, this parameter has become the first priority in clinical practice, especially for its value in determining prognosis and therapeutic choices. ” This was said by Robin Foà, professor emeritus of Hematology at Sapienza University of Rome, today in Milan, during the event in which Amgen described the results of the clinical study of Phase III E1910 which was shown as the introduction of monoclonal antibody bispecific blinatumomab in the first line of treatment significantly increases the overall survival of patients with newly diagnosed Ph-B lymphocyte acute lymphoblastic leukemia (ALL).
“In pathology such as acute lymphoblastic leukemia, MRD monitoring is very important, because it is the only way in which you can set the best therapy for each patient – the professor continued – However, to collect accurate and reliable data. It is important that the studies are carried out in approved institutions, with quality controls, using the same manufacturing processes and following strict deadlines. For this reason, in Italy from 1996 it was decided to centralize the “study of” the samples of patients with ALL registered in the clinical procedures of Gimema, the group of elderly hematological diseases of Italy in Rome , in Sapienza. MRD monitoring was then carried out, and in Rome, in 2 other centers: one in Bergamo and one in Palermo. It is important to highlight that all 3 companies use the same molecular biology techniques (quantitative PCR), following a European standard. Making even the slightest mistake in monitoring MRD – concludes Foà – can really be a decisive factor for the patient’s survival”.
#Blinatumomab #drug #MDR #oncohematology